Compare Invesco S&P 500 Momentum ETF (SPMO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs 10X Genomics Inc — how do they compare? Invesco S&P 500 Momentum ETF trades at $151.33 (market cap $23.48B), while 10X Genomics Inc trades at $82.39 (market cap $10.07B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 2.3× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 1,876,152). Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Momentum ETF for 54 Days and 10X Genomics Inc for 92 Days on average.
| SPMO | TXG | |
|---|---|---|
Market Cap | $23.48B | $10.07B |
Volume | 1,876,152 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $97.74 |
52-Week Low | $107.84 | $11.48 |
Typical Hold Time | 54 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPMO trades at $153.00, showing minimal daily movement with a 0.01% gain. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators suggest neutral momentum. Recent portfolio reconstitution added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest remains strong with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
The momentum-focused ETF offers concentrated exposure to S&P 500's fastest-rising stocks, historically outperforming the broader index. Key risks include sector concentration in technology and higher volatility. Analyst sentiment remains positive given the fund's structural momentum advantage and institutional accumulation trends.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
